Abstract:Background: Acute mountain sickness (AMS) is the most prevalent condition resulting from hypobaric hypoxia (HH) at high altitudes. Although evidence suggests the involvement of inflammatory cytokines in AMS development, there is currently a lack of reports on variations in cytokine levels between individuals susceptible to AMS and those resistant to AMS prior to ascending to high altitude. Thus our current study aims to assess the predictive capability for AMS occurrence by evaluating differences in cytokine levels at low altitudes. Methods: The present study recruited 48 participants, who ascended from low altitude to middle high-altitude (3700 m) and further to extreme high-altitude (5000 m). Based on Lake Louise Score (LLS) at the two high altitudes, participants were categorized into severe AMS-susceptible (sAMS), moderate AMS-susceptible (mAMS), and non-AMS groups. The Bio-Plex MAGPIX System was employed to measure plasma levels of 11 inflammatory cytokines. Cytokines at low altitude and middle high-altitude were analyzed through receiver operating characteristic (ROC) analysis to obtain area under the ROC curve (AUROC), sensitivity, and specificity. Results: Based on LLS at 3700 m, we initially categorized the study subjects into the sAMS group (n = 8) and the Non-AMS group (n = 40). Among individuals in the non-AMS group (n = 40) at the altitude of 3700 m, those who developed AMS at the altitude of 5000 m were assigned to the mAMS group (n = 17), whereas those who did not experience AMS were included into the non-AMS group (n = 23). The concentration of TNF-α at low altitude exhibited robust predictive performance for predicting AMS occurrence at the altitude of 3700 m. Among the non-AMS group at the altitude of 3700 m, we identified that the concentration of IL-2 and IL-17A demonstrated high efficacy in predicting the onset of AMS following ascent to 5000 m. In addition, differentially expressed cytokines including IL-17A, TNF-α and IL-2 at low altitude possessed discriminatory potential among the three groups at 5000 m.. Conclusion: We posited that the levels of TNF-α, IL-2, IL-17A in serum of low altitude could be considered as potential biomarkers to predict the occurrence of AMS at high altitude. New & noteworthy: Through the two comparisons at different two altitudes (baseline level and 3700 m), we provided a model to progressively screen individuals who are susceptible and resistant to different high altitudes (3700 m and 5000 m). TNF-α could firstly screen out the AMS susceptible individuals at the altitude of 3700 m. And through its combination with IL-2 and IL-17A, we could further screen out AMS susceptible individuals at the altitude of 5000 m.

Identification of Novel Serum Peptide Biomarkers for High-Altitude Adaptation: a Comparative Approach

Identification of Novel Urine Proteomic Biomarkers for High Stamina in High-Altitude Adaptation.

Alterations of Human Plasma Proteome Profile on Adaptation to High-Altitude Hypobaric Hypoxia

Serum Inflammatory Factor Profiles in the Pathogenesis of High-Altitude Polycythemia and Mechanisms of Acclimation to High Altitudes

Potential plasma biomarkers at low altitude for prediction of acute mountain sickness

Metabolite Modulation in Human Plasma in the Early Phase of Acclimatization to Hypobaric Hypoxia

IL-2, IL-17A and TNF-α hold potential as biomarkers for predicting acute mountain sickness prior to ascent

Nuclear magnetic resonance spectroscopic characteristics of hypoxic stress peptide(HSP) and changes of HSP in people exposed rapidly to high altitude

Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort

Proteomic and Clinical Biomarkers for Acute Mountain Sickness Diagnosis, Prognosis, Protection, and Pathogenesis in a Longitudinal Cohort

Key Genes FECH and ALAS2 under Acute High-Altitude Exposure: A Gene Expression and Network Analysis Based on Expression Profile Data

Metabolomic analysis of human plasma sample after exposed to high altitude and return to sea level

Differentially expressed plasma proteins in high-altitude polycythemia patients based on technique of TMT combined with mass spectrometry

Exploring the Blood Biomarkers and Potential Therapeutic Agents for Human Acute Mountain Sickness Based on Transcriptomic Analysis, Inflammatory Infiltrates and Molecular Docking

Preliminary screening of biomarkers in HAPE based on quasi-targeted metabolomics

Differential Plasma Proteome Analysis in Patients with High-Altitude Pulmonary Edema at the Acute and Recovery Phases.

Exploration of Acute Phase Proteins and Inflammatory Cytokines in Early Stage Diagnosis of Acute Mountain Sickness.

Cognitive Impairment Mechanisms in High-Altitude Exposure: Proteomic and Metabolomic Insights

Identification of key pathways, genes and immune cell infiltration in hypoxia of high-altitude acclimatization via meta-analysis and integrated bioinformatics analysis

Application of the hypoxia stress peptide in the high altitude disease rehabilitative treatment

CHANGES OF INTERLEUKIN-6 IN PATIENTS WITH ACUTE HIGH ALTITUDE CEREBRAL EDEMA